





© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim 2911wileyonlinelibrary.com
A Truncated IL-17RC Peptide Ameliorates Synovitis and 
Bone Destruction of Arthritic Mice
Yuxuan Du, Yulong Tong, Wentong Mei, Junhui Jia, Menglin Niu, Wei Cao, Weiwei Lou, 
Shentao Li, Zhanguo Li, W. Alexander Stinson, Huihui Yuan,* and Wenming Zhao*
DOI: 10.1002/adhm.201600668
Y. Du, Y. Tong, W. Mei, Dr. M. Niu, Dr. W. Cao, W. Lou,  
Dr. S. Li, Dr. H. Yuan, Prof. W. Zhao
Department of Immunology
School of Basic Medical Sciences
Capital Medical University
No. 10 Xitoutiao, You An Men  
Beijing 100069, P. R. China
E-mail: huihui_yuan@163.com; zhao-wenming@163.com
Dr. J. Jia
Department of Blood transfusion
Aerospace Center Hospital
No.15, Yuquan Road, Haidian District, Beijing 100049, P. R. China
Dr. Z. Li
Department of Rheumatology & Immunology
Clinical Immunology Center
Peking University People’s Hospital
No. 11 Xizhimen South Street, Beijing 100044, P. R. China
W. A. Stinson
Department of Internal Medicine
Division of Rheumatology
University of Michigan
Ann Arbor, MI 48109, USA
Peptide-based therapy, such as modified peptides, has attracted increased 
attention. IL-17 is a promising therapeutic target for autoimmune diseases, 
and levels of circulating bioactive IL-17 are associated with rheumatoid 
arthritis severity. In this study, a modified truncated IL-17RC is generated 
to ameliorate inflammation and bone destruction in arthritis. The truncated 
IL-17RC binds to both IL-17A and IL-17F with higher binding capacity com-
pared to nonmodified IL-17RC. In addition, the truncated IL-17RC reduces 
the secretion of inflammatory and osteoclastogenic factors induced by 
IL-17A/F in vitro. Moreover, the administration of truncated IL-17RC dra-
matically improves symptoms of inflammation and inhibited bone destruc-
tion in collagen-induced arthritis mice. Collectively, these data demonstrate 
that modified truncated IL-17RC peptide may be a more effective treatment 
strategy in the simultaneous inhibition of both IL-17A and IL-17F signaling, 
whereas the existing agents neutralize IL-17A or IL-17F alone. These suggest 
that the truncated IL-17RC may be a potential candidate in the treatment of 
inflammatory associated bone diseases.
leading to severe disability and increased 
mortality.[1] Numerous studies have dem-
onstrated that interleukin (IL)-17A and, 
to a lesser extent, IL-17F contribute to dis-
ease progression and severity in RA.[2,3] 
Studies in experimental arthritis models 
demonstrate a detrimental role of IL-17 
in the triggering of inflammatory cytokine 
cascades that appear to be critical in bone 
destruction.[4,5] Previous studies suggest 
that IL-17 stimulates the secretion of other 
factors such as IL-6, tumor necrosis factor 
(TNF)-α, and IL-1β in fibroblasts, osteo-
blasts, and osteoclasts, further aggravating 
the inflammation.[6,7] Also, these cytokines 
affect the release of other inflammatory 
and osteoclastogenic factors associated 
with RA.[8–10] Indeed, IL-17 has been dem-
onstrated to induce the secretion of matrix 
metalloproteinases (MMPs) to enhance 
matrix degradation in articular carti-
lage explants and inhibit the synthesis of 
proteoglycan and collagen.[11,12] Moreover, IL-17 up-regulates 
receptor activator nuclear factor-κB ligand (RANKL) expression 
in osteoblasts, which lead to osteoclast differentiation, resulting 
in bone erosion.[13,14] Therefore, blocking of IL-17 may lead to 
the abolishment of downstream signalling effects and thus pre-
vent various inflammatory disorders.
Within the IL-17 family, IL-17A is most closely related to 
IL-17F.[15] IL-17A and IL-17F can form homodimer complexes 
(AA, FF) and a heterodimer complex (AF) that can all bind to 
the IL-17 heterodimer receptor complex (IL-17R), consisting 
of IL-17RA and IL-17RC. The IL-17R induces the activation 
of the nuclear factor kappa-light-chain enhancer of activated 
B cells (NF-κB) and mitogen-activated protein kinase (MAPK) 
signaling pathways to trigger transcription factors. Upon 
ligand binding, IL-17RC recruits the adaptor Act1/CIKS 
linked to TNF receptor-associated factor 6 (TRAF6) adaptor 
through a homotypic SEF/IL-17R (SEFIR) domain docking 
interaction. IL-17RC-bound Act1 oligomerizes with IL-17RA-
bound Act1, resulting in an effective recruitment of interme-
diates for efficient IL-17-dependent signal transduction.[15] In 
the context of RA, both IL-17A and IL-17F mediated signalling 
through the IL-17R can induce the expression of proinflam-
matory cytokines and osteoclastogenic factors.[2,3] Accordingly, 
the IL-17 pathway has emerged as a potential therapeutic 
target in the treatment of RA.[16,17] Compared to IL-17RA, IL-
17RC binds with similarly high affinity to both IL-17A and 
1. Introduction
Rheumatoid arthritis (RA) is an immune-mediated disease 
characterized by inflammation and subsequent bone damage 
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IL-17F.[18] Targeting IL-17RC may be a more effective treat-
ment strategy in the simultaneous inhibition of both IL-17A 
and IL-17F signaling, whereas the existing agents neutralize 
IL-17A or IL-17F alone.[19,20] A direct approach for targeting 
the pathway would involve the use of antibodies or modified 
peptides that might bind to IL-17A/F with high binding capa-
bility, and thus prevent the ligands bind to the endogenous 
receptors. Compared with neutralizing antibodies, modified 
peptides displayed some advantages in production progress 
and therapeutic effects, such as low molecular weight, the 
ability to specifically targeting, low toxicity, and easy avail-
ability. Therefore, we engineered a truncated IL-17RC peptide 
in prokaryotic expression system that modified the binding 
domain of native IL-17RC, yet lacks the transmembrane and 
intracellular signal transducing domains, which could block 
immediate intracellular signaling events, as well as more 
distal events such as the release of proinflammatory cytokines 
and chemokines to characterize it as high binding capability, 
low immunogenicity, dual functions, and convenient produc-
tion and purification. Our aim was to evaluate whether trun-
cated IL-17RC could ameliorate symptoms of inflammation 
and bone destruction in arthritic mice through inhibiting the 
pathogenic roles of IL-17A/F. We tested our protein’s ability 
to inhibit cytokine release from cells and we developed two 
different arthritis models to test its effects in vivo. We found 
that truncated IL-17RC ameliorated symptoms of inflamma-
tion and bone destruction in arthritic mice through inhibiting 
the pathogenic roles of IL-17A/F, suggesting its potential as a 
drug candidate for RA.
2. Results
2.1. Construction and Characterization of Truncated IL-17RC 
Peptide
A recombinant pET42a-prokaryotic expression plasmid was 
constructed to express truncated IL-17RC peptide (Figure 1). 
The component and purity of this peptide were analyzed by 
mass spectroscopy (MS) and high performance liquid chroma-
tography (HPLC) (Supplementary Figure 1). After ultrfiltration, 
the final concentration of truncated IL-17RC was 2 mg mL−1 
(Figure 2a) and its predicted size was ≈19 kDa (Figure 2b). 
The binding assay showed that truncated IL-17RC bound both 
IL-17A and IL-17F, and the absorbance value of IL-17A was 
higher than IL-17F. Meanwhile, the detectable levels of IL-
17A/F were increased in a dose-dependent manner from 0.1 
to 10 μg mL−1 IL-17RC (Figure 2c,d). With truncated IL-17RC 
as capture protein, compared with nonmodified IL-17RC, no 
significant differences were observed in the detectable levels 
between IL-17A and IL-17F (Figure 2e). Conversely, the detect-
able levels of the ligands significantly decreased when using 
nonmodified IL-17RC (Figure 2f).
2.2. Inhibition of Truncated IL-17RC Peptide In Vitro
In preosteoblasts (MC3T3-E1), treatment of truncated IL-17RC 
peptide prominently inhibited the secretion of IL-6 by 22.89% 
(IL-17A) and 20.85% (IL-17F) (Figure 3a). In parallel with IL-6 
levels, IL-17RC protein also reduced TNF-α by 28.21% (IL-17A) 
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Figure 1. Construction of truncated IL-17RC peptide. a) Sequence alignment of IL-17RC exon 8 to 12. b) Agarose gel electrophoresis of undigested 
pET42a-IL-17RC plasmid (Lane 1), Nde I and Not I-digested recombinant plasmid (Lane 2) and pET42a-IL-17RC plasmid PCR products (Lane 3). Lane 
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and 34.97% (IL-17F) (Figure 3b). Similarly, within the fibro-
blasts (NIH/3T3), significant reductions in the expression of 
IL-6 and TNF-α were observed in the truncated IL-17RC group, 
for example, a ≈50% decrease in IL-6 secretion (Figure 3d,e).
Subsequently, IL-17RC treatment reduced the RANKL 
level to 52.72% in the IL-17A stimulated group or 45.63% in 
the IL-17F stimulated group (Figure 3c). In preosteoclasts 
(RAW264.7), the production of MMP-9 also showed a ≈30% 
decrease upon IL-17RC treatment (Figure 3f). After treatment 
with truncated IL-17RC, osteoclast differentiation was also com-
pletely prevented (Figure 3g) and the number of osteoclast-like 
cells was significantly reduced even in the presence of IL-17A/F 
in vitro (Figure 3h).
2.3. Protection from Inflammation and Joint Damage by Trun-
cated IL-17RC Peptide in Collagen-Induced Arthritis (CIA) Mice
In the CIA model, the incidence of mice treated with trun-
cated IL-17RC was reduced 42.86% at day 37 (Figure 4a). 
Moreover, the clinical scores were lower in IL-17RC-treated 
mice than in CIA group (Figure 4b). Mean-
while, the hind-paw swelling was allevi-
ated gradually between days 30 and 37 
(Figure 4c). Compared to CIA group, IL-
17RC reduced synovitis, pannus formation 
(Figure 4d), and joint damage (Figure 4e) 
as determined by inflammatory (Figure 4g) 
and cartilage scores (Figure 4h). Severe 
bone erosion was observed in interphalan-
geal and ankle joints of CIA mice, while 
bone integrity was preserved in truncated 
IL-17RC treated group (Figure 4f). Radio-
graphic analysis showed that BV/TV, BS/
BV, Ct. BMD, and DA were remarkably 
improved in the truncated IL-17RC treated 
group (Figure 4i–l).
2.4. Effects of Truncated IL-17RC Peptide on 
Cytokine Production in CIA Mice
Compared to the CIA group, truncated IL-
17RC treatment significantly reduced serum 
levels of IL-6, TNF-α, monocyte chemot-
actic protein (MCP)-1, interferon (IFN)-γ, 
RANKL, and MMP-9 on day 28. Similarly, 
IL-6, MCP-1, RANKL, and MMP-9 expres-
sion were significantly lower on day 37 in 
truncated IL-17RC treated mice compared to 
CIA group (Figure 5a–i). In addition, osteo-
clastogenesis analysis with tartrate resistant 
acid phosphatase (TRAP) staining showed 
that truncated IL-17RC blocked osteoclast 
differentiation (Figure 5j,k) and significantly 
reduced the number of TRAP-positive cells 
(Figure 5l).
2.5. Neutralization of Truncated IL-17RC Peptide in Knee Joints
In the CIA-IL-17A/F arthritis, truncated IL-17RC treated 
groups exhibited significantly decreased clinical knee scores 
and swelling compared to the IL-17A or IL-17F injected groups 
from days 29–36 (Figure 6a–d). The incidence and hind-paw 
clinical scores and swelling were also reduced in the truncated 
IL-17RC treated mice (Figure 6e), in line with previous observa-
tions (Figure 4a–c). Histological analysis for synovial inflamma-
tion (Figure 6f) and overall destruction of cartilage (Figure 6g) 
were significantly lower ≈40% in the truncated IL-17RC group 
(Figure 6j,k). Accordingly, osteoclastogenesis assays showed 
that truncated IL-17RC inhibited osteoclast mature (Figure 6h,i) 
and significantly decreased the number of osteoclast-like cells 
under cartilage (Figure 6l).
2.6. Prevention of Truncated IL-17RC Peptide in IL-17-Induced 
Bone Destruction
In micro-CT imaging analysis, focal bone erosion, thinning of 
cortical bone and loss of trabecular bone were observed on the 
Adv. Healthcare Mater. 2016, 5, 2911–2921
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Figure 2. Preparation of truncated IL-17RC peptide. a) Expression and purity analysis of trun-
cated IL-17RC peptide by SDS-PAGE. b) Recognition analysis of truncated IL-17RC peptide by 
anti-IL-17RC or anti-His-tag antibody by Western blotting. c,d) Binding assay of truncated IL-
17RC peptide with IL-17A or IL-17F (n = 3/group). e,f) Competition assay of truncated IL-17RC 
peptide binding to IL-17A or IL-17F in comparison with nonmodified standard (n = 3/group). 
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2D micro-CT images in close proximity to the facet joint. In 
contrast, treatment with IL-17RC alleviated the above patholog-
ical changes (Figure 7a,b). Further quantitative analysis showed 
that Ct. BMD was also remarkably increased by 5.2% (IL-17A) 
and 6.1% (IL-17F) in truncated IL-17RC treated group com-
pared with IL-17A or IL-17F induced groups (Figure 7c). In par-
allel with cortical bone, a significant increase in Tb. BMD, Ct. 
Th, Tb. Th, and Tb. N were observed after IL-17RC treatment 
in IL-17A-injected mice or IL-17F-injected group (Figure 7d–g). 
As for Tb. Sp, there was a ≈30% reduction following truncated 
IL-17RC treatment (Figure 7h).
3. Discussion
In the present study we engineered a truncated IL-17RC pep-
tide that could bind both IL-17A and IL-17F. Our data show that 
truncated IL-17RC can effectively outcompete a nonmodified 
IL-17RC protein for the ligands IL-17A and IL-17F and reduce 
the secretion of inflammatory and osteoclastogenic factors 
induced by IL-17A/F. Moreover, the administration of truncated 
IL-17RC led to a dramatic improvement of inflammation and 
reduction of radiological bone destruction. These findings sup-
port our hypothesis that the truncated IL-17RC has a dual effect 
to alleviate inflammation and bone resorption through inhib-
iting the downstream effects of IL-17A/F.
Previous data showed that its contribution of IL-17A/F 
to bone erosion and synovitis and blocking of endogenous 
IL-17 prevented joint destruction and significantly suppressed 
inflammation of arthritic models.[21,22] These findings suggest 
the therapeutic potential of anti-IL-17 treatment in ameliorating 
arthritic flares and further bone deformation. In the past ten 
years, a few potential therapeutic strategies targeting IL-17 have 
been developed, including anti-IL-17A/F antibodies, anti-IL-17R 
antibodies and soluble IL-17RA peptides.[17] However, many of 
these studies have only looked at anti-IL-17A treatments and 
not IL-17A/F together. These biological products are in dif-
ferent stages of clinical trial for several diseases including RA, 
Crohn’s disease, and psoriasis.[23] Compared with neutralizing 
antibodies, soluble receptors can effectively compete with the 
Adv. Healthcare Mater. 2016, 5, 2911–2921
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Figure 3. Inhibition of truncated IL-17RC peptide in vitro. a–f) ELISA assay of IL-6, TNF-α, MMP-9 or RANKL in NIH/3T3, MC3T3-E1, or RAW264.7 
treated with IL-17A or IL-17F with or without truncated IL-17RC peptide for 48 h or 7 d (n = 3/group). g) TRAP staining of osteoclastogenesis assay in 
a coculture system for RAW264.7 and MC3T3-E1 for 7 d with or without truncated IL-17RC peptide. Scale bar, 50 μm. h) The number of osteoclast-like 
TRAP-positive in IL-17A or IL-17F with or without truncated IL-17RC peptide (n = 10/group). The data are expressed as the means ± SD/SEM, *p < 
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endogenous receptors for the native ligand binding sites.[24] In 
addition, low immunogenicity makes them more suitable for 
application, such as Etanercept, a soluble TNF-α receptor.[25] 
As shown from previous studies of IL-17RC splice variants, 
exon 8 and exon 12 are required for IL-17A/F binding to IL-
17RC, while exon 7 is not.[18] Therefore, we removed the low 
homologous segments and unnecessary binding sequences as 
well as the transmembrane and intracellular signal transducing 
regions of IL-17RC. There was no observed loss in binding 
ability to IL-17A/F. At the same concentration of protein, our 
truncated IL-17RC peptide outcompeted a nonmodified IL-
17RC for the ligands IL-17A/F. This suggests that our protein 
could have therapeutic potential in the inhibition of IL-17A/F.
The high expression of IL-17 in the joints and synovial fluid 
of RA patients triggers the secretion of various proinflamma-
tory cytokines and chemokines from synovial fibroblasts, T 
cells and macrophages, such as IL-6, IL-8, and MMPs.[26,27] 
Furthermore, IL-17 also stimulates the expression of matrix 
MMPs and RANKL to induce cartilage destruction. We tested 
our protein’s ability to inhibit IL-17A/F induced cytokine release 
Adv. Healthcare Mater. 2016, 5, 2911–2921
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Figure 4. Protection of truncated IL-17RC peptide in CIA mice. a–c) The incidence, clinical scores and hind-paw swelling in control, CIA and truncated 
IL-17RC-treated C57BL/6 mice (n = 12/group). d,e,g,h) H&E, TB staining, and histological scores of hind paw in each group (n = 16/group). Scale bar, 
50 μm. f) Radiographic analysis of interphalangeal and carpal joints on three-dimensional micro-CT images. i–l) Bone parameters analysis of BV/TV, 
BS/BV, Ct.BMD, and DA in each group (n = 10/group). The asterisk represents inflammatory cells (d) and the arrows represent the thinning cartilage 
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from fibroblasts, osteoblasts, and osteoclasts. We found a 
significant decrease in the release of IL-6, TNF-α, RANKL, 
and MMP-9 from these cells (Figure 3). Fortunately, similar 
inhibitory effects were observed despite additional injections of 
either IL-17A or IL-17F, indicating our protein could effectively 
inhibit cell surface IL-17R binding and subsequent cytokine 
release stimulated by either protein (Figure 5). In addition, in 
the preosteoclast and preosteoblast coculture system, truncated 
IL-17RC impaired the differentiation and maturation of osteo-
clasts as indicated by TRAP staining, an uncontrolled process 
in inflammatory diseases that results in bone deformation.
We chose the CIA model to evaluate the effect of truncated 
IL-17RC peptide in vivo as it shares similar immunological and 
pathological features with RA.[28] In parallel with RA patients, 
the expression of IL-17A and IL-17F is significantly increased in 
the sera and in local joints of CIA mice.[29,30] In our model, trun-
cated IL-17RC-treated mice had greatly diminished in clinical 
signs and levels of the pro-inflammatory cytokines IL-6, TNF-α, 
MCP-1, IFN-γ, RANKL, and MMP-9 compared to the CIA mice 
(Figures 4 and 5). These results indicate that truncated IL-17RC 
inhibited the progression of arthritis and affirmed our in vitro 
findings. Furthermore, we then wanted to affirm its inhibitory 
effects on IL-17A and IL-17F in vivo and determine its protec-
tion of bone damage in the context of IL-17. We repeated the 
CIA model again, but gave additional injections of IL-17A and 
IL-17F into the knee joint cavity on days 28 and 32 of the model. 
We found that IL-17A and IL-17F significantly aggravated syno-
vitis severity and joint damage in the arthritic mice. Treatment 
Adv. Healthcare Mater. 2016, 5, 2911–2921
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Figure 5. Interventions of truncated IL-17RC peptide in CIA mice. a–f) Cytometric bead array of IL-6, TNF-α, MCP-1, IFN-γ, IL-10, and IL-12p70 in serum 
of control, CIA and truncated IL-17RC mice after immunization with chicken type II collagen for days 0, 14, 28, and 37 (n = 5/group). g–i) ELISA assay 
of RANKL, MMP-9, and OPG in serum of each group (n = 6/group). j–k) TRAP staining of sections of tibiae derived from sacrificed animals. j) Scale 
bar, 100 μm and k) 50 μm. (l) The number of osteoclast-like TRAP-positive in each group (n = 16/group). The arrows represent the mature osteoclasts 
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with truncated IL-17RC, however, inhibited inflammation and 
prevented further bone deformation, as determined by clinical 
scores and radiological examination, respectively.
In fact, IL-17A and IL-17F have many overlapping functions 
including immunity to extracellular pathogens and neutrophil 
recruitment, while their cytokine knockout models indicate that 
IL-17A plays a more significant role in IL-17-mediated inflam-
mation.[15] That might partly explain that the secretions of 
inflammatory cytokines were higher in IL-17A group even in 
the presence of truncated IL-17RC compared to IL-17F. While, 
the inhibition of truncated IL-17RC treatment in IL-17A group 
was higher compared to IL-17F group. However, no significant 
Adv. Healthcare Mater. 2016, 5, 2911–2921
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Figure 6. Neutralization of truncated IL-17RC in local joint. a–d) Clinical scores and knee swelling in CIA, IL-17A/F-injected and truncated IL-17RC-
treated mice (n = 14/group). e) The incidence, hind-paw clinical scores and swelling on the day before sacrifice (n = 14/group). f–i) H&E, TB, and 
TRAP staining of knee joints in each group. f–h) Scale bar, 100 μm and i) 50 μm. j–k) Histological scores of knee joints in each group (n = 8/group). 
l) The number of osteoclast-like TRAP-positive in each group (n = 8/group). The asterisks represent inflammatory cells (f) and the arrows represent 
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difference was observed between IL-17A and IL-17F group after 
treated with truncated IL-17RC. The possible explanations were 
that the conditions of experiments are comparable complex to 
lead variable data in vitro and in vivo, such as different sys-
tems in enzyme-linked immunosorbent assay (ELISA). Besides, 
IL-17A and IL-17F shared some similarities in structures and 
pathological functions between human and mouse, because the 
homology of the truncated peptide (IL-17RC) is comparative of 
high (Supplementary Figure 2, Supporting Information).
Our results demonstrate our protein’s highly effective 
capacity at inhibiting IL-17A/F. Not only does it bind with 
high affinity to its ligands, it prevents IL-17 associated cytokine 
release, and osteoclast maturation, findings that were corrobo-
rated in vivo. Unfortunately, we were unable to include other 
marketed IL-17 inhibitory drugs (such as secukinumab) as 
comparison or in conjunction with our protein, but our results 
do indicate the therapeutic potential of truncated IL-17RC. The 
immediate challenges that still remain includes optimizing its 
pharmacokinetics and prolonging the half-life (Supplemen-
tary Figure 3, Supporting Information) of truncated IL-17RC 
by PEGylation[31] or other biomaterial assisted drug delivery 
approaches in the future.
4. Conclusions
In conclusion, the truncated IL-17RC peptide alleviated inflam-
mation and bone resorption through simultaneous neutraliza-
tion of IL-17A and IL-17F-driven pathogenesis in vitro and in 
vivo. This study highlights its high binding capability, low 
immunogenicity, dual functions, and convenient production and 
purification as a desired approach. Therefore, we anticipate this 
Figure 7. Prevention of truncated IL-17RC in IL-17-induced bone destruction. a,b) Radiographic analysis of knee joints on 3D micro-CT images. 
c–h) Bone parameters analysis of Ct.BMD, Tb.BMD, Ct.Th, Tb.Th, Tb.N, and Tb.Sp in each group (n = 5/group). The arrows represent bone destruction 
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modified soluble receptor might serve as a potential candidate 
in treating IL-17 associated inflammatory diseases such as RA.
5. Experimental Section
Cell Lines and Mice: The murine calvarial cell line (MC3T3-E1), murine 
fibroblast cell line (NIH/3T3), and murine monocyte/macrophage cell 
line (RAW264.7) were all obtained from the Chinese Academy of Medical 
Sciences and Peking Union Medical College. The cell culture media were 
all purchased from GE Healthcare Life Sciences (South Logan, Utah, 
USA). The cells were separately cultured in Dulbecco’s modification 
of Eagle’s medium (DMEM)-high glucose (MC3T3-E1), DMEM-low 
glucose (RAW264.7), and α-minimum essential medium (MEM) 
(NIH/3T3) supplemented with 10% fetal bovine serum (FBS) at 37 °C in 
a humidified atmosphere of 5% CO2.
Male C57BL/6 mice (10 weeks old) were purchased from Beijing Vital 
River Laboratories (VRL) Co., Ltd. All mice were housed in a controlled 
environment and allowed food and water ad libitum. All experiments 
were conducted in accordance with the requirements of the Animal 
Care and Use Committee of Capital Medical University (Permit ID: 
SCXK-2012-0001).
Reagents: Antibodies used were as follows: goat anti-human IL-17RC 
antibodies and goat anti-human IL-17A or IL-17F biotinylated antibody 
(R&D Systems, Minneapolis, MN, USA), mouse anti-His-tag antibody 
(Merck, Millipore, Darmstadt, Germany) and horseradish peroxidase 
(HRP)-conjugated rabbit anti-goat or mouse IgG secondary antibodies 
(Protein Tech Group, Inc, Chicago, USA). The recombinant proteins 
that were used included human IL-17A/F and IL-17RC (R&D Systems, 
Minneapolis, MN, USA) and chick collagen type II (CII) (Chondrex, 
Morwell Diagnostic, Zurich, Switzerland). The commercial kits that 
were used included TRAP kit (Sigma-Aldrich, Saint Louis, MO, USA); 
Trizol RNA purification kit and a first strand cDNA synthesis kit (Life 
Technologies, California, USA); cytometric bead array (CBA) mouse 
inflammation kits (BD Bioscience, Allentown, PA, USA); mouse 
DuoSet ELISA development system and IL-6/TNF-α/RANKL/MMP-9/
osteoprotegerin (OPG) ELISA kits (all from R&D Systems, Minneapolis, 
MN, USA). Freund’s complete and incomplete adjuvants were obtained 
from Chondrex (Morwell Diagnostic, Zurich, Switzerland).
Construction of Truncated IL-17RC Peptide Expression Vector: To 
maximize the bioactivity of human truncated IL-17RC, a recombinant 
pET42a-prokaryotic expression plasmid was constructed containing 
the binding domain of IL-17RC spanning exons 8 to 12.[18] The 
truncated IL-17RC sequence was amplified by polymerase chain 
reaction (PCR) from the plasmid including human IL-17RC ORF 
sequence (Invitrogen Life Technologies, California, USA) with the 
N-terminal primer 5′-CGCCATATGGCCCTGCCCTGGCTCAACGT-3′ 
(Nde I site is underlined) and the C-terminal primer 
5′-ATTTGCGGCCGCCTGAACACAGAGGTTAGGGT-3′ (Not I site is 
underlined). The PCR product was digested with NdeΙ and NotI, 
ligated into the corresponding sites of the pET-42a plasmid, and then 
transformed into E. coli BL21 (DE3) for protein expression. The plasmid 
also contains a His-tag sequence to enable purification.
Expression and Purification of Truncated IL-17RC Peptide: A 5 L 
Erlenmeyer flask containing 1 L of 2×YT medium supplemented with 
25 μg mL−1 kanamycin was inoculated with 1 mL of an overnight culture 
of E. coli BL21 (DE3) pET42a carrying the truncated IL-17RC cDNA. The 
flask was shaken at 250 rpm at 37 °C until the optical density (OD600) 
reached 0.6–0.8. Subsequently, isopropyl-β-d-thiogalactoside (IPTG, 
0.4 × 10−3 m) was added to the culture and the temperature was shifted to 
16 °C for 5 h to induce truncated IL-17RC peptide expression. Next, the 
cell pellets were collected by centrifugation, resuspended in precooled 
phosphate buffer saline (PBS) and lysed by ultrasonication in an ice-cold 
water bath using an ultrasonic processor (VCX-600, Sonic & Materials, 
USA). The cell lysate was centrifuged at 13 000 rpm for 30 min at 4 °C 
to separate supernatant and precipitated. After filtering with 0.45 μm 
durapore membrane filters (SLHU033RB, Merck Millipore, Germany), 
the supernatant was loaded onto a HisTrap affinity columns (GE 
Healthcare Life Technology, USA) followed by elution with an increasing 
gradient of 20 × 10−3, 40 × 10−3, 60 × 10−3, 80 × 10−3, 100 × 10−3, and 
500 × 10−3 m imidazole. The eluted protein was then concentrated, salts 
removed, and buffers exchanged using Macrosep Advance Centrifugal 
Device MWCO 3K (Pall Life Sciences, USA).
Identification of Truncated IL-17RC Peptide: The total protein 
expression was confirmed by sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE) and Western blotting. For SDS-
PAGE analysis, cell lysates were separated by 15% resolving gel and 
visualized by Coomassie brilliant blue R-250. For Western blotting, the 
sample was further transferred onto polyvinylidene fluoride (PVDF) 
membranes (Millipore Corporation, Billerica, MA, USA). The membrane 
was blocked with 5% skim milk in TBST (TBS with 0.05% Tween-20) 
2 h at room temperature and then incubated with a polyclonal goat anti-
IL-17RC antibodies (0.1 μg mL−1) or a monoclonal mouse anti-His-tag 
antibody (0.1 μg mL−1) overnight at 4 °C. After washing three times with 
TBST, the membrane was incubated with HRP-conjugated rabbit anti-
goat IgG (1:10000) or rabbit anti-mouse IgG (1:10000) for 1 h at room 
temperature. After washing three times, the membrane was exposed 
to a SuperSignal West Pico ECL system (Thermo Fisher Scientific Inc., 
Waltham, USA) and visualized using Fusion Solo S (Vilber Lourmat, 
Belgium).
Binding and Competition Assays of Truncated IL-17RC Peptide: The 
ELISA system was developed to test the dose dependence of IL-17A or 
IL-17F binding to the truncated IL-17RC peptide. Ninety-six-well Maxisorp 
microtitre plates were coated with a 10-fold serial dilution of truncated 
IL-17RC peptide (10−3–103 μg mL−1, 100 μL per well) overnight at 4 °C. 
The plates were blocked with 1% bovine serum albumin (BSA) in PBS, 
followed by the addition of 100 μL of IL-17A or IL-17F (100 ng mL−1), and 
incubated overnight at 4 °C. After washing with PBST (PBS with 0.05% 
Tween-20), goat anti-human IL-17A biotinylated antibody (0.2 μg mL−1) 
or goat anti-human IL-17F biotinylated antibody (0.2 μg mL−1) were 
added, and the plates were incubated for 2 h at 37 °C. After washing, 
streptavidin-HRP was added to each well and the plates were incubated 
for 20 min at room temperature. After adding the substrate solution and 
stop solution, the absorbance was read at 450 nm by a microplate reader 
(Thermomax Technologies).
Furthermore, a modified competitive ELISA system was established 
to determine whether the truncated IL-17RC peptide could outcompete 
a nonmodified IL-17RC protein for IL-17A or IL-17F at the optimal 
concentration determined above. Ninety-six-well plates were coated with 
truncated IL-17RC peptide (10 μg mL−1) overnight at 4 °C. The plate 
was blocked with 1% BSA in PBS, and IL-17A or IL-17F (100 ng mL−1) 
with or without nonmodified IL-17RC (10 μg mL−1) was added to 
determine the binding capacity of truncated IL-17RC peptide. In a separate 
experiment, plates were coated with nonmodified IL-17RC (10 μg mL−1) 
overnight and then treated with IL-17A or IL-17F (100 ng mL−1) 
with and without truncated IL-17RC peptide (10 μg mL−1). The plates 
were washed and then treated with biotinylated antibodies to IL-17A 
and IL-17F (0.2 μg mL−1) and washed again. The absorbance of each 
well was measured at 450 nm by a microplate reader (Thermomax 
Technologies).
Neutralization of Truncated IL-17RC Peptide: The cells were all placed 
onto 96-well plates and stimulated with IL-17A or IL-17F (3 ng mL−1) 
in the presence or absence of truncated IL-17RC peptide (300 ng mL−1) 
for 48 h or 7 d. First, the levels of IL-6 and TNF-α were determined in 
supernatants of MC3T3-E1 or NIH/3T3 at a density of 5 × 104 cells per 
well after 48 h. In addition, the level of RANKL was further evaluated in 
supernatants of MC3T3-E1 (1 × 104 cells per well) after 7 d. The cytokine 
concentrations were measured by mouse DuoSet ELISA development 
system according to the manufacturers’ instructions. Then, mouse total 
MMP-9 ELISA kit was used to determine its secretion from RAW264.7 
cells at a density of 5 × 103 cells per well after 7 d.
Coculture System and Osteoclastogenesis Assay: A coculture system 
for RAW264.7 and MC3T3-E1 was established using Transwell inserts 
(Corning, USA).[32,33] RAW264.7 cells (3 × 104 cells per well) were seeded 







2920 wileyonlinelibrary.com © 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim Adv. Healthcare Mater. 2016, 5, 2911–2921
www.advhealthmat.de
www.MaterialsViews.com
embedded in the lower compartment of each Transwell. This coculture 
system was maintained in DMEM with IL-17A or IL-17F (10 ng mL−1) 
treatment in the presence or absence of truncated IL-17RC (1 μg mL−1) 
for 7 d. The cells were then subjected to TRAP staining using an acid 
phosphatase kit, and the number of osteoclast-like TRAP-positive cells 
(multinucleated cells, MNCs > 3 nuclei) was counted.
Induction of CIA: In the first CIA model, 100 μL chick type II collagen 
dissolved in 0.01 m acetic acid to a concentration of 4 mg mL−1 was 
emulsified in an equal volume of Freund’s complete adjuvant and 
administered intradermally at the base of the tail of C57BL/6N mice 
(15 mice per group). On day 21, a booster emulsion prepared with 
type II collagen and Freund’s incomplete adjuvant was administered 
intradermally near the primary injection site.[34–36] The truncated IL-17RC 
peptide (150 μg, 100 μL) was injected intraperitoneally three times per 
week on day 14 after the initial immunization whereas PBS was used 
as a control. The hind-paw was scored every day and the swelling was 
measured every 3 d. On day 37 after the first immunization, mice 
were anesthetized. The clinical scores were assigned as previously 
described.[36]
In the CIA-IL-17A/F mouse model, IL-17A or IL-17F (200 ng in 10 μL 
PBS) was injected into the knee joints on day 28 and day 32 after the first 
injection of chick type II collagen.[37–39] The truncated IL-17RC peptide 
(150 μg, 100 μL) was injected intraperitoneally three times per week on 
day 14 after the initial immunization whereas PBS was used as a control. 
The knee joints were scored and measured from day 28. On day 37 after 
the first immunization, mice were anesthetized. Knee joint damage was 
scored visually after knee joint skin dissection under intraperitoneal 
anaesthesia as previously described.[38]
Histological Analysis: Murine hind paws and knee joints were removed 
postmortem, stored in 10% neutral formalin, decalcified in 20% 
ethylenediamine tetraacetic acid (EDTA) for 4 weeks, then dehydrated 
and embedded in paraffin. Sections were cut along the longitudinal axis, 
mounted and stained with hematoxylin and eosin (H&E) or toluidine 
blue (TB). The severity of inflammatory cell infiltration in joint and 
cartilage destruction was scored according previously described.[40]
Radiographic Analysis: Quantitative analysis of the hind paw and knee 
joints was performed after sacrifice using a micro-CT system (SKYSCAN 
1172; Bruker, Belgium). 3D analysis was performed using CTAn software 
(Bruker). The fraction of bone surface (BS), bone volume (BV), bone 
surface/bone volume (BS/BV), percent bone volume (BV/TV), cortex 
bone mineral density (Ct. BMD), cortex area (Ct. Ar), cortex thickness 
(Ct. Th), trabecular bone mineral density (Tb. BMD), trabecular number 
(Tb. N), trabecular thickness (Tb. Th), trabecular separation (Tb. 
Sp), and degree of anisotropy (DA) were analyzed using the built-in 
software.[41,42]
Serological Analysis: Serum cytokines were measured on day 0, 14, 28, 
and 37 at which times the mice were euthanized. The blood (10–15 drops) 
was extracted from mouse orbital veins. The concentrations of IL-6, 
TNF-α, MCP-1, IFN-γ, IL-10, and IL-12p70 in serum were measured 
using CBA mouse inflammation kits. The concentration of RANKL, 
OPG or MMP-9 in serum was measured using mouse ELISA kits. All 
procedures were performed according to the manufacturers’ protocols.
Statistical Analysis: The data were analysed using a statistical package 
(SPSS13.0, Chicago, IL, USA). The Student’s t-test or one-way analysis 
of variance for parametric analysis was utilized for between-group 
comparisons. A p-value less than 0.05 was considered to be statistically 
significant.
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